# Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

> **NCT00858364** · PHASE3 · TERMINATED · sponsor: **Amgen** · enrollment: 2549 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Anemia
- Cancer
- Lung Cancer

## Interventions

- **DRUG:** Darbepoetin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00858364
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07-17
- **Primary completion:** 2017-06-07
- **Final completion:** 2017-06-07
- **Target enrollment:** 2549 (ACTUAL)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00858364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00858364, "Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00858364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*